Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,351-1,375 of 2,022
CompletedNCT03666715

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Portugal
Sponsor
Janssen-Cilag Farmaceutica Ltda.
Condition
Schizophrenia
Enrolling By InvitationNCT05619822

A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand how people respond to a therapy or guided support program in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Spain
Sponsor
Universidad Complutense de Madrid
Condition
Schizophrenia
CompletedNCT06941909

The Effect of a Mindfulness-Based Self-Compassion Program on Care Burden, Life Satisfaction, and Coping Levels of Caregivers of Individuals With Schizophrenia

This study exists to see whether a therapy or guided support program can play a useful role in care. Researchers are trying to understand whether a therapy or guided support program can make support easier to access outside standard clinic visits.

SchizophreniaOtherOver 18 Years
Countries
Turkey
Sponsor
Neslihan Lok
Condition
Schizophrenia
RecruitingNCT05284721

Family Peer Navigator for Early Psychosis for Black Families

This study exists to see whether this type of care is workable and worth testing more broadly. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
Washington State University
Condition
Schizophrenia
RecruitingNCT02455193

Neuronal Effects of Exercise in Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 21 Years to 70 Years
Countries
United States
Sponsor
University of Colorado, Denver
Condition
Schizophrenia
RecruitingNCT06542640

Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis

This study exists to understand how blood tests and biological markers holds up over time after the earliest research stage. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 15 Years to 35 Years
Countries
China
Sponsor
Beth Israel Deaconess Medical Center
Condition
Schizophrenia
TerminatedNCT03220438

TMS Enhancement of Visual Plasticity in Schizophrenia

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT03874494

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
China
Sponsor
Otsuka Beijing Research Institute
Condition
Schizophrenia
Not Yet RecruitingNCT06923891

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United States
Sponsor
Vanguard Research Group
Condition
Schizophrenia
Not Yet RecruitingNCT06924255

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Collaborative Neuroscience Research, LLC
Condition
Schizophrenia
CompletedNCT00688259

Cognitive-Behavioral Therapy in Veterans With Schizophrenia

This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
WithdrawnNCT06878833

A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

This study exists to understand what helps the medication LYN-005 work in everyday practice, not just under ideal conditions. Researchers are trying to understand how people respond to the medication LYN-005 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Global
Sponsor
Lyndra Inc.
Condition
Schizophrenia
CompletedNCT03510325

Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)

This study exists to learn from real-world information that can show how a therapy or guided support program fits into care. Researchers are trying to understand how people respond to a therapy or guided support program in practice and what may need to be adjusted.

SchizophreniaOtherFrom 16 Years to 45 Years
Countries
China
Sponsor
Shanghai Mental Health Center
Condition
Schizophrenia
Active Not RecruitingNCT03911726

Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia

This study exists to explore whether smoking support or smoking-related treatment could improve care and understanding. Researchers are trying to understand whether smoking support or smoking-related treatment can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Germany
Sponsor
Central Institute of Mental Health, Mannheim
Condition
Schizophrenia
CompletedNCT01119014

Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 12 Years to 17 Years
Countries
Denmark
Sponsor
Anne Katrine Pagsberg
Condition
Schizophrenia
TerminatedNCT05462340

PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia

This study exists to compare options and see whether brain scans or other body measurements offers something meaningfully different. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Washington University School of Medicine
Condition
Schizophrenia
RecruitingNCT06907420

40 Hz Visual Stimulation as an Intervention in Schizophrenia

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherOver 18 Years
Countries
Germany
Sponsor
Technical University of Munich
Condition
Schizophrenia
CompletedNCT06906224

Effects of Buspirone Combined With Clozapine

This study exists to see whether a therapy or guided support program can make care clearer and more responsive. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 1 Year to 65 Years
Countries
China
Sponsor
Chuanfu Song
Condition
Schizophrenia
CompletedNCT03271242

Implementation of National Guidelines for Treatment of Psychoses

This study exists to understand what helps psychoeducation, a guided learning and support program, work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can give earlier or clearer feedback during care.

SchizophreniaOtherOver 16 Years
Countries
Global
Sponsor
University Hospital, Akershus
Condition
Schizophrenia
RecruitingNCT06692530

Asylumseekers Experiencing Paranoid Delusions: A Virtual Reality Study

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherOver 18 Years
Countries
Netherlands
Sponsor
University Medical Center Groningen
Condition
Schizophrenia
CompletedNCT06572449

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia